Leqvio Appetite & Cravings Changes: What the Clinical Evidence Actually Shows

Does Inclisiran Change Appetite or Cravings?

No published trial data show that inclisiran causes meaningful appetite or craving changes in humans. The ORION-10 (N=1,561) and ORION-11 (N=1,617) phase 3 trials, published together in the New England Journal of Medicine in 2020, did not list appetite increase, appetite decrease, or food-craving alterations among adverse events occurring at a frequency greater than placebo in either active-treatment arm [1]. Participants received 284 mg of inclisiran subcutaneously on Day 1, Day 90, and then every 180 days thereafter.

The FDA prescribing information for Leqvio, last updated after the December 2021 approval, does not list appetite changes, nausea, or craving-related symptoms in its adverse-reaction table [2]. This matters clinically because patients switching from or combining inclisiran with other lipid-lowering or cardiometabolic therapies sometimes attribute appetite shifts to the newer agent.

Why the Mechanism Predicts No Appetite Effect

Inclisiran works through RNA interference. After subcutaneous injection, it is taken up by hepatocytes via asialoglycoprotein receptors (GalNAc conjugation) and silences PCSK9 mRNA inside liver cells [3]. The drug does not cross the blood-brain barrier. It has no known activity at GLP-1 receptors, ghrelin receptors, leptin receptors, or any other pathway linked to hunger signaling. This mechanistic profile makes appetite alteration biologically implausible at therapeutic doses.

What ORION-10 and ORION-11 Actually Measured

In ORION-10, inclisiran reduced LDL-C by 52.3% from baseline at Day 510 versus a 1.8% reduction with placebo (P<0.001) [1]. In ORION-11, the time-averaged LDL-C reduction from Day 90 to Day 540 was 49.9% versus placebo (P<0.001) [1]. Body weight was not a primary or secondary endpoint in either study. Researchers did track it as a safety measure, and no statistically significant between-group difference was observed in either trial. The adverse-event profile was dominated by injection-site reactions (2.6% inclisiran vs. 0.9% placebo in ORION-10), not systemic symptoms [1].

The PCSK9 Pathway and Appetite: Is There Any Biological Link?

PCSK9 is a serine protease that degrades LDL receptors on hepatocytes. Blocking it, whether with monoclonal antibodies or siRNA, raises receptor density and lowers circulating LDL-C [3]. The question of whether PCSK9 itself has any peripheral role in metabolism beyond cholesterol handling is still being studied in preclinical models.

Preclinical Signals: Interesting but Not Clinically Translated

A 2021 paper in the Journal of Lipid Research reported that PCSK9 knockout mice showed modest changes in adipose tissue lipid handling compared with wild-type controls [4]. The authors were explicit that these findings could not be extrapolated to humans receiving therapeutic PCSK9 inhibition. No randomized controlled trial in humans has reproduced a metabolic or appetite-related effect from PCSK9 suppression, by any mechanism.

Monoclonal Antibodies vs. SiRNA: Same Pathway, Same Appetite Null Finding

Evolocumab (Repatha) and alirocumab (Praluent), the PCSK9 monoclonal antibodies approved before inclisiran, also show no appetite signal in their key trials. The FOURIER trial (N=27,564) of evolocumab reported no appetite or weight-change adverse events distinguishable from placebo at a median follow-up of 2.2 years [5]. If inhibiting PCSK9 protein through antibodies produces no appetite effect at that scale, the mechanistic argument against inclisiran causing such effects becomes even stronger.

Body Weight on Inclisiran: Reading the Data Carefully

Neither ORION-10 nor ORION-11 was powered to detect body-weight changes. Mean baseline body-mass index in both trials was approximately 31 kg/m2, consistent with overweight-to-obese cardiovascular populations [1]. Participants were not placed on dietary interventions specific to the trials. Stable statin background therapy was required.

What "No Significant Weight Change" Actually Means

In both ORION trials, the inclisiran arms did not show a statistically or clinically meaningful change in body weight relative to placebo at any measured time point. This is different from saying patients lost no weight on their own. Some participants, already receiving statins and lifestyle counseling as part of standard cardiovascular care, lost weight independently. The drug itself did not appear to contribute to or counteract those changes.

Confounding in Real-World Reports

Patients prescribed inclisiran often have multiple concurrent cardiometabolic conditions and may simultaneously start or adjust other medications (statins at higher doses, ezetimibe, or GLP-1 receptor agonists for overlapping cardiovascular indications). Real-world reports of appetite changes in this population are almost certainly attributable to those concurrent therapies rather than inclisiran. Semaglutide 2.4 mg (Wegovy), for example, produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo in STEP-1 (N=1,961) [6], a magnitude that would dominate any appetite signal from a concurrent PCSK9 siRNA.

Adverse Events That Patients Do Experience on Inclisiran

The adverse effects that appear with genuine frequency above placebo in the ORION program are injection-site reactions and, at low rates, bronchitis and nasopharyngitis [1]. No gastrointestinal events, no nausea, and no appetite-linked symptoms crossed the threshold for inclusion in the pooled safety table.

Injection-Site Reactions: The Real Side Effect to Counsel Patients About

In ORION-10, injection-site reactions occurred in 2.6% of inclisiran-treated patients versus 0.9% of placebo patients [1]. These are typically mild, transient, and resolve without intervention. They include erythema, pain at the injection site, and occasional small indurations. The reactions are mechanistically unrelated to any systemic metabolic process.

Serious Adverse Events: No Appetite-Related Serious Events

Serious adverse events were balanced between inclisiran and placebo arms in both ORION-10 and ORION-11. No serious adverse event related to appetite, weight, or gastrointestinal function was attributed to inclisiran in either trial [1]. The FDA's review of the pooled ORION safety database reaching over 3,000 patient-years of exposure confirmed this profile before approval [2].

Clinical Guidance: What to Tell Patients Asking About Appetite

Clinicians can use a straightforward three-step framework when patients raise appetite concerns about inclisiran:

Step 1. Confirm the timeline. Ask when the appetite change started relative to the most recent inclisiran injection (Day 1, Day 90, or a 6-month maintenance dose). Inclisiran peaks in plasma within 4 hours and is largely cleared from circulation within days; hepatic silencing persists, but systemic drug exposure does not [3]. Appetite changes appearing weeks after an injection are almost certainly unrelated.

Step 2. Audit the full medication list. Statins rarely cause appetite changes, but high-intensity statin initiation can cause transient gastrointestinal upset. Ezetimibe occasionally causes abdominal discomfort. Any concurrent GLP-1 receptor agonist will drive meaningful appetite suppression. Identify the most likely causal agent before attributing the symptom to inclisiran.

Step 3. Reference the prescribing information directly. The FDA label for Leqvio does not list appetite changes as an adverse reaction [2]. Sharing this with patients who have read anecdotal online reports provides evidence-based reassurance grounded in the regulatory document, not just clinician opinion.

When to Investigate Further

If a patient on inclisiran reports significant unintentional weight loss of more than 5% over 6 months, that warrants investigation independent of drug causation. Patients with ASCVD or HeFH carry cardiovascular risk profiles that can include conditions (cancer, advanced heart failure, thyroid disease) that produce weight loss through non-pharmacologic mechanisms. The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease recommends evaluating unexplained weight loss as a potential marker of underlying disease in high-risk patients [7].

ORION-10 and ORION-11 in Context: Understanding the Trial Populations

The ORION-10 trial enrolled patients with ASCVD in the United States already on maximally tolerated statin therapy. Mean baseline LDL-C was 104.0 mg/dL. At Day 510, inclisiran reduced LDL-C to 50.5 mg/dL in the active arm versus 103.0 mg/dL in the placebo arm [1]. The ORION-11 trial enrolled a broader population (Europe and North America) including both ASCVD and HeFH patients, achieving nearly identical LDL-C reduction percentages at comparable time points [1].

Background Statin Use and Metabolic Confounding

All ORION-10 and ORION-11 participants were required to be on stable lipid-lowering therapy for at least 3 months before randomization. This controlled for the most common confounders of metabolic change in this population. Stable background statin therapy is not associated with appetite changes at therapeutic doses according to a 2019 Cochrane review of statin tolerability (N=246,955 participants across 135 trials) [8].

What the 17-Month Follow-Up Adds

Seventeen months of follow-up in ORION-10 and 18 months in ORION-11 provide a longer window than most phase 3 lipid trials. If inclisiran caused cumulative metabolic effects on appetite, this duration would have been sufficient to detect them. The absence of such a signal across 3,178 combined participants over that follow-up period is the strongest available clinical evidence that the drug does not alter hunger physiology.

Inclisiran and GLP-1 Combination Therapy: An Emerging Area

Patients with both elevated LDL-C and obesity often qualify for both inclisiran (for ASCVD risk reduction) and a GLP-1 receptor agonist (for weight management or type 2 diabetes). In this combination setting, appetite changes are expected from the GLP-1 component and are not attributable to inclisiran.

What the ACC Recommends for Combination Use

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states that PCSK9 inhibitors, including siRNA agents, may be combined with GLP-1 receptor agonists without pharmacokinetic or pharmacodynamic concern [9]. No interaction studies have identified appetite-related additive effects. The appetite suppression observed in patients on both drugs should be managed according to GLP-1 prescribing principles, not attributed to inclisiran.

Practical Titration Consideration

When initiating both therapies simultaneously, starting the GLP-1 agonist first and up-titrating over 16 to 20 weeks before adding inclisiran allows clinicians to establish an appetite-change baseline attributable clearly to the GLP-1 component. Inclisiran's Day 1 / Day 90 / every-6-months schedule makes it relatively easy to sequence after GLP-1 stabilization without losing LDL-C-lowering time.

Patient-Reported Experience: Online Reports vs. Trial Data

Anecdotal reports on patient forums sometimes describe appetite changes after inclisiran injections. These reports merit attention but must be weighed against the controlled-trial evidence. The nocebo effect, where patients experience symptoms they expect based on reading about other drugs or side-effect lists, is well-documented for injectable therapies. A 2020 meta-analysis in JAMA Internal Medicine found that nocebo responses accounted for up to 76% of statin-attributed muscle symptoms across 12 blinded trials [10]. A similar dynamic may apply to appetite symptoms in patients receiving inclisiran who are also reading about GLP-1 drugs in the same cardiovascular-care context.

What Clinicians Should Document

When a patient reports appetite changes on inclisiran, documenting the following supports accurate attribution: date of most recent injection, current full medication list, baseline weight at drug initiation, current weight, and any recent dietary or lifestyle changes. This documentation also supports any pharmacovigilance reporting that may eventually contribute to post-marketing safety surveillance.

Summary of Key Evidence Points

The evidence against inclisiran causing appetite or craving changes rests on four pillars. First, the mechanism is restricted to hepatic PCSK9 mRNA silencing with no CNS or gut-hormone activity [3]. Second, ORION-10 (N=1,561) and ORION-11 (N=1,617) found no appetite-related adverse events above placebo rates [1]. Third, the FDA prescribing label for Leqvio lists no appetite changes in its adverse-reaction section [2]. Fourth, the class-level signal is absent: evolocumab in FOURIER (N=27,564) showed no appetite or weight-change findings across 2.2 years of follow-up [5].

Patients asking about this topic deserve a direct answer: inclisiran does not appear to affect hunger or cravings based on available evidence. Any appetite changes experienced during inclisiran therapy should be evaluated by reviewing the full medication list, starting with any concurrent GLP-1 receptor agonist, and considering non-pharmacologic causes. Per the FDA-approved prescribing information for Leqvio, the next maintenance injection for patients who are stable is due every 6 months from the Month 3 dose, and no dose adjustment is required based on metabolic parameters [2].